Unknown

Dataset Information

0

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.


ABSTRACT: RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of ALN-RSV01 in adults experimentally infected with wild-type RSV. Eighty-eight healthy subjects were enrolled into a randomized, double-blind, placebo-controlled trial. A nasal spray of ALN-RSV01 or saline placebo was administered daily for 2 days before and for 3 days after RSV inoculation. RSV was measured serially in nasal washes using several different viral assays. Intranasal ALN-RSV01 was well tolerated, exhibiting a safety profile similar to saline placebo. The proportion of culture-defined RSV infections was 71.4 and 44.2% in placebo and ALN-RSV01 recipients, respectively (P = 0.009), representing a 38% decrease in the number of infected and a 95% increase in the number of uninfected subjects. The acquisition of infection over time was significantly lower in ALN-RSV01 recipients (P = 0.007 and P = 0.03, viral culture and PCR, respectively). Multiple logistic regression analysis showed that the ALN-RSV01 antiviral effect was independent of other factors, including preexisting RSV antibody and intranasal proinflammatory cytokine concentrations. ALN-RSV01 has significant antiviral activity against human RSV infection, thus establishing a unique proof-of-concept for an RNAi therapeutic in humans and providing the basis for further evaluation in naturally infected children and adults.

SUBMITTER: DeVincenzo J 

PROVIDER: S-EPMC2889365 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.

DeVincenzo John J   Lambkin-Williams Robert R   Wilkinson Tom T   Cehelsky Jeffrey J   Nochur Sara S   Walsh Edward E   Meyers Rachel R   Gollob Jared J   Vaishnaw Akshay A  

Proceedings of the National Academy of Sciences of the United States of America 20100426 19


RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of AL  ...[more]

Similar Datasets

| S-EPMC6701032 | biostudies-literature
| S-EPMC7548429 | biostudies-literature
| S-EPMC4077042 | biostudies-other
2016-07-15 | E-GEOD-76003 | biostudies-arrayexpress
| S-EPMC7108134 | biostudies-literature
2016-07-15 | GSE76003 | GEO
| S-EPMC5947135 | biostudies-other
2017-02-09 | GSE74988 | GEO
2019-12-13 | GSE132648 | GEO
2024-07-10 | MSV000095296 | MassIVE